Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 12/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6718730 | 0.93 | PTGS2 (0.38) | PTGS2PTGS1ABCB11ALDH1A1GHSR | |
| SCHEMBL6729465 | 0.91 | PTGS2 (0.35) | PTGS2PTGS1GHSRPPARGPPARD | |
| SCHEMBL6733949 | 0.89 | PTGS1 (0.35) | PTGS2PTGS1ABCB11ALDH1A1PPARG | |
| SCHEMBL6733678 | 0.87 | PTGS2 (0.32) | PTGS2PTGS1PPARGPPARDPPARA | |
| SCHEMBL6723358 | 0.86 | CA1 (0.38) | PTGS2PTGS1 | |
| SCHEMBL6722621 | 0.86 | PTGS2 (0.38) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL6720055 | 0.85 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL6730037 | 0.85 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL7111728 | 0.84 | SCN5A (0.35) | PTGS2PTGS1PPARGPPARDPPARA | |
| SCHEMBL6718602 | 0.84 | PTGS2 (0.36) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885PTGS1 4/4885ABCB11 2898/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885PTGS1 4/4885ABCB11 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.